Log in

NASDAQ:CFMS - ConforMIS Stock Price, Forecast & News

-0.05 (-4.55 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $1.05
50-Day Range
MA: $1.15
52-Week Range
Now: $1.05
Volume857,800 shs
Average Volume657,889 shs
Market Capitalization$72.15 million
P/E RatioN/A
Dividend YieldN/A
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:CFMS



Sales & Book Value

Annual Sales$89.79 million
Book Value$0.57 per share


Net Income$-43,370,000.00


Market Cap$72.15 million
Next Earnings Date3/2/2020 (Confirmed)
OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) released its quarterly earnings results on Wednesday, October, 30th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The medical instruments supplier earned $17.30 million during the quarter, compared to analysts' expectations of $17.80 million. ConforMIS had a negative return on equity of 115.71% and a negative net margin of 41.36%. View ConforMIS's Earnings History.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for ConforMIS.

How can I listen to ConforMIS's earnings call?

ConforMIS will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has ConforMIS issued on next quarter's earnings?

ConforMIS updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $19.9-19.9 million, compared to the consensus revenue estimate of $20.21 million.

What price target have analysts set for CFMS?

2 brokers have issued 12 month price targets for ConforMIS's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate ConforMIS's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for ConforMIS.

What is the consensus analysts' recommendation for ConforMIS?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:
  • 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (11/4/2019)
  • 2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019)

Has ConforMIS been receiving favorable news coverage?

News articles about CFMS stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ConforMIS earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near term. View News Stories for ConforMIS.

Are investors shorting ConforMIS?

ConforMIS saw a drop in short interest in January. As of January 31st, there was short interest totalling 3,060,000 shares, a drop of 13.6% from the January 15th total of 3,540,000 shares. Based on an average trading volume of 551,400 shares, the days-to-cover ratio is currently 5.5 days. Approximately 4.8% of the shares of the stock are sold short. View ConforMIS's Current Options Chain.

Who are some of ConforMIS's key competitors?

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), NVIDIA (NVDA), Micron Technology (MU), AT&T (T), Advanced Micro Devices (AMD), Cisco Systems (CSCO), AbbVie (ABBV), Alibaba Group (BABA), Pfizer (PFE) and Intel (INTC).

Who are ConforMIS's key executives?

ConforMIS's management team includes the folowing people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Ed Kilgallen, VP of Operations
  • Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are ConforMIS's major shareholders?

ConforMIS's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.22%), Archon Capital Management LLC (6.34%), Geode Capital Management LLC (2.17%), State Street Corp (2.01%), AQR Capital Management LLC (1.94%) and UBS Group AG (1.19%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, Erin Henry, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.

Which major investors are selling ConforMIS stock?

CFMS stock was sold by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, AQR Capital Management LLC, Oxford Asset Management LLP, Renaissance Technologies LLC, Secrest Blakey & Associates LLC and Creative Planning. Company insiders that have sold ConforMIS company stock in the last year include Archon Capital Management Llc, Bradley Langdale, Erin Henry, Mark A Augusti, Patricia A Davis and Paul S Weiner. View Insider Buying and Selling for ConforMIS.

Which major investors are buying ConforMIS stock?

CFMS stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, UBS Group AG, ARK Investment Management LLC, Alambic Investment Management L.P., Goldman Sachs Group Inc., Citigroup Inc. and Barclays PLC. View Insider Buying and Selling for ConforMIS.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $1.05.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $72.15 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. ConforMIS employs 262 workers across the globe.View Additional Information About ConforMIS.

What is ConforMIS's official website?

The official website for ConforMIS is http://www.conformis.com/.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel